Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332488 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 547
- Enrollment target
NCT00332488: Completed Phase 3 study, sponsored by Mannkind Corporation.
NCT00332488 is a Phase 3 study that has completed, run by Mannkind Corporation. The registered enrollment target is 547 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00332488, a Phase 3 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 547 participants
- Enrollment target
Study Summary
to demonstrate the efficacy of inhaled Technosphere/Insulin in combination with metformin versus combination metformin and a secretagogue
Interventions
- DRUG Technosphere Insulin
- DRUG Metformin & Secretagogues
- DRUG Technosphere Insulin & Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 547 participants |
| Start Date | 2004-12 |
| Phase | Phase 3 |
What the finished NCT00332488 record still lists
NCT00332488 is an interventional study that assigns participants to a tested intervention. The registered 547 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 3 interventions - of which Technosphere Insulin is the first listed.
NCT00332488 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00332488 about?
NCT00332488 is a clinical study titled "Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes". to demonstrate the efficacy of inhaled Technosphere/Insulin in combination with metformin versus combination metformin and a secretagogue
What is the current status of trial NCT00332488?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 547 participants. The study started on 2004-12.
What interventions are being tested in trial NCT00332488?
The interventions under investigation include: Technosphere Insulin (DRUG), Metformin & Secretagogues (DRUG), Technosphere Insulin & Metformin (DRUG).
Who is sponsoring clinical trial NCT00332488?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00332488's enrollment target sits among peer trials
547 689th of 2000 higher than 1,312 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
- NCT06850922 · 546 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia